Table 2.

Estimating the prevalence of ARPKD using Cerner Health Facts^® Data.

	HF ARPKD patients (0–29 years)	HF (0–29 years)	US population (0–29 years)a	HF/US population (0–29 years) (%)	ARPKD patients (0–29 years)b	Annualized prevalence (per 100,000)
2010	55	6,228,323	126,025,383	4.94	1,113	0.88
2011	78	7,140,758	126,252,347	5.66	1,379	1.09
2012	89	6,858,426	126,452,548	5.42	1,641	1.30
2013	76	6,996,558	127,084,385	5.51	1,380	1.09
2014	112	7,727,920	127,326,557	6.07	1,845	1.45
AVG	82	6,990,397	126,628,244	5.52	1,485	1.17

^aFrom NVS data set.

^bCorrected for US population.

ARPKD, autosomal recessive polycystic kidney disease; HF, Health Facts^® Dataset (using discharge data); NVS, National Vital Statistics data.